• Isatuximab and cemiplimab combined therapy shows durable responses and manageable safety in relapsed/refractory NK/T-cell lymphoma.

  • Structural variations disrupting the 3’-UTR of PD-L1 and high PD-L1 expression were related with response to this combination therapy.

Abstract

This study aimed to assess the efficacy and safety of combining cemiplimab, an anti–programmed cell death protein 1 (PD-1) antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD-1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) IV every 4 weeks for 6 cycles. Responders then received cemiplimab (350 mg) and isatuximab (10 mg/kg) every 3 weeks for up to 24 months. The primary end point was the complete response (CR) rate based on the best response. Of 37 patients enrolled, the CR rate was 51% (19/37), exceeding the primary end point of 40%, and the objective response rate was 65% (24/37). After a median follow-up of 30.2 months (95% confidence interval [CI], 25.6-34.8 months), the median progression-free survival was 9.5 months (95% CI, 1.4-17.6 months), whereas the median overall survival had not yet been reached. Patients achieving CR received a median of 28 cycles (range, 4-33 cycles), and the median duration of response for responders (n = 24) was 29.4 months (95% CI, 15.4-43.4 months). Structural variations disrupting the 3’-untranslated region of PD-L1 and high programmed death ligand 1 (PD-L1) expression were observed in responders. Most adverse events were mild (grade 1-2), with grade ≥3 events (32%) and no treatment-related deaths. The combination of isatuximab and cemiplimab demonstrated sustained antitumor activity and a manageable safety profile in R/R ENKTL. This phase 2 trial is registered at www.clinicaltrials.gov as number NCT04763616.

1.
Kim
WS
,
Song
SY
,
Ahn
YC
, et al
.
CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?
.
Ann Oncol
.
2001
;
12
(
3
):
349
-
352
.
2.
Au
WY
,
Weisenburger
DD
,
Intragumtornchai
T
, et al
.
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
.
Blood
.
2009
;
113
(
17
):
3931
-
3937
.
3.
Yamaguchi
M
,
Kwong
YL
,
Kim
WS
, et al
.
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study
.
J Clin Oncol
.
2011
;
29
(
33
):
4410
-
4416
.
4.
Kim
SJ
,
Kim
K
,
Kim
BS
, et al
.
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study
.
J Clin Oncol
.
2009
;
27
(
35
):
6027
-
6032
.
5.
Kim
SJ
,
Yoon
SE
,
Kim
WS
.
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
.
J Hematol Oncol
.
2018
;
11
(
1
):
140
.
6.
Yamaguchi
M
,
Suzuki
R
,
Oguchi
M
.
Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type
.
Blood
.
2018
;
131
(
23
):
2528
-
2540
.
7.
Lim
SH
,
Hong
JY
,
Lim
ST
, et al
.
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
.
Ann Oncol
.
2017
;
28
(
9
):
2199
-
2205
.
8.
Jeong
SH
,
Song
HN
,
Park
JS
, et al
.
Allogeneic stem cell transplantation for patients with natural killer/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation
.
Biol Blood Marrow Transpl
.
2018
;
24
(
12
):
2471
-
2478
.
9.
Kwong
YL
,
Chan
TSY
,
Tan
D
, et al
.
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
.
Blood
.
2017
;
129
(
17
):
2437
-
2442
.
10.
Li
X
,
Cheng
Y
,
Zhang
M
, et al
.
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
.
J Hematol Oncol
.
2018
;
11
(
1
):
15
.
11.
Kim
S-J
,
Hyeon
J
,
Cho
I
,
Ko
YH
,
Kim
WS
.
Comparison of efficacy of pembrolizumab between Epstein-Barr virus‒positive and‒negative relapsed or refractory non-Hodgkin lymphomas
.
Cancer Res Treat
.
2019
;
51
(
2
):
611
-
622
.
12.
Lee
JY
,
Kwon
JH
,
Hur
JY
, et al
.
Pembrolizumab for patients with relapsed or refractory extranodal NK/T-cell lymphoma in Korea
.
Cancer Res Treat
.
2024
;
56
(
2
):
681
-
687
.
13.
Yoon
SE
,
Cho
H
,
Berning
P
, et al
.
Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma
.
Ann Hematol
.
2024
;
103
(
10
):
4171
-
4181
.
14.
Tian
J
,
Hao
M
,
Liu
Q
, et al
.
Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural killer/T cell lymphoma: a retrospective study
.
Hematol Oncol
.
2023
;
41
(
3
):
396
-
406
.
15.
Tao
R
,
Fan
L
,
Song
Y
, et al
.
Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
.
Signal Transduct Target Ther
.
2021
;
6
(
1
):
365
.
16.
Kim
SJ
,
Lim
JQ
,
Laurensia
Y
, et al
.
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
.
Blood
.
2020
;
136
(
24
):
2754
-
2763
.
17.
Huang
H
,
Tao
R
,
Hao
S
, et al
.
Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study
.
J Clin Oncol
.
2023
;
41
(
16
):
3032
-
3041
.
18.
Chen
L
,
Diao
L
,
Yang
Y
, et al
.
CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
.
Cancer Discov
.
2018
;
8
(
9
):
1156
-
1175
.
19.
Feng
X
,
Zhang
L
,
Acharya
C
, et al
.
Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma
.
Clin Cancer Res
.
2017
;
23
(
15
):
4290
-
4300
.
20.
Carlo-Stella
C
,
Zinzani
PL
,
Sureda
A
, et al
.
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
.
Hematol Oncol
.
2023
;
41
(
1
):
108
-
119
.
21.
Wang
L
,
Wang
H
,
Li
PF
, et al
.
CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type
.
Ann Hematol
.
2015
;
94
(
8
):
1381
-
1388
.
22.
Cheson
BD
,
Fisher
RI
,
Barrington
SF
, et al
.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
.
J Clin Oncol
.
2014
;
32
(
27
):
3059
-
3068
.
23.
Kim
SJ
,
Yoon
DH
,
Jaccard
A
, et al
.
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
.
Lancet Oncol
.
2016
;
17
(
3
):
389
-
400
.
24.
Nagato
T
,
Ohkuri
T
,
Ohara
K
, et al
.
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy
.
Cancer Immunol Immunother
.
2017
;
66
(
7
):
877
-
890
.
25.
Cho
J
,
Kim
SJ
,
Park
WY
, et al
.
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
.
Mod Pathol
.
2020
;
33
(
4
):
603
-
615
.
26.
Lim
JQ
,
Huang
D
,
Chan
JY
, et al
.
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort
.
Am J Hematol
.
2022
;
97
(
9
):
1159
-
1169
.
27.
Lim
JQ
,
Huang
D
,
Tang
T
, et al
.
Whole-genome sequencing identifies responders to pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
.
Leukemia
.
2020
;
34
(
12
):
3413
-
3419
.
28.
Kataoka
K
,
Miyoshi
H
,
Sakata
S
, et al
.
Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
.
Leukemia
.
2019
;
33
(
7
):
1687
-
1699
.
29.
Wang
JH
,
Bi
XW
,
Li
PF
, et al
.
Overexpression of MYC and BCL2 predicts poor prognosis in patients with extranodal NK/T-cell lymphoma, nasal type
.
J Cancer
.
2017
;
8
(
5
):
793
-
800
.
30.
Xiong
J
,
Cui
BW
,
Wang
N
, et al
.
Genomic and transcriptomic characterization of natural killer T cell lymphoma
.
Cancer Cell
.
2020
;
37
(
3
):
403
-
419.e6
.
31.
Chang
YC
,
Tsai
HJ
,
Huang
TY
, et al
.
Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations
.
Ann Hematol
.
2024
;
103
(
8
):
2917
-
2930
.
32.
Sung
E
,
Ko
M
,
Won
JY
, et al
.
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
.
Mol Ther
.
2022
;
30
(
8
):
2800
-
2816
.
33.
Simon
R
.
Optimal two-stage designs for phase II clinical trials
.
Control Clin Trials
.
1989
;
10
(
1
):
1
-
10
.
34.
Cho
J
.
Basic immunohistochemistry for lymphoma diagnosis
.
Blood Res
.
2022
;
57
(
S1
):
55
-
61
.
35.
Song
TL
,
Nairismägi
M-L
,
Laurensia
Y
, et al
.
Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma
.
Blood
.
2018
;
132
(
11
):
1146
-
1158
.
36.
Huang
H
,
Zhu
J
,
Yao
M
, et al
.
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
.
J Hematol Oncol
.
2021
;
14
(
1
):
25
.
37.
Fox
CP
,
Civallero
M
,
Ko
YH
, et al
.
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell project
.
Lancet Haematol
.
2020
;
7
(
4
):
e284
-
e294
.
38.
Yoon
SE
,
Song
Y
,
Kim
SJ
, et al
.
Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia
.
Lancet Reg Health West Pac
.
2021
;
10
:
100126
.
You do not currently have access to this content.
Sign in via your Institution